Regeneron (REGN) Q1 2025: ILEA U.S. Sales Plunge 39% as Copay Funding Gap Shifts Market Dynamics

April 29, 2025 | By EarningsIQ Research

Regeneron’s Q1 was defined by a sharp contraction in its ILEA retinal franchise, driven by a patient copay funding gap that accelerated share loss to lower-cost Avastin, even as its flagship immunology and oncology brands continued to gain ground. The company’s pipeline and capital allocation remain robust, but the evolving reimbursement environment and regulatory scrutiny are reshaping the near-term outlook for its core ophthalmology business.

Summary

• Retinal Franchise Hit by Funding Gap: ILEA U.S. demand fell sharply as copay assistance disruptions pushed patients to cheaper alternatives.
• Immunology and Oncology Portfolio Drives Growth: Dupixent and Libtio delivered broad-based gains and expanded into new indications.
• Regulatory and Reimbursement Uncertainty Looms: Ongoing FDA device reviews and changes in patient assistance funding create operational headwinds.

Performance Analysis

Regeneron’s Q1 2025 performance was bifurcated by marked weakness in its U.S. ophthalmology segment and strong expansion across its immunology and oncology portfolios. The company’s flagship retinal product, ILEA, saw a dramatic drop in U.S. net sales, down 39% year-over-year and 38% sequentially, attributed primarily to a sudden increase in use of off-label Avastin, a lower-cost alternative, as a result of a funding gap at patient copay assistance foundations. Physician unit demand for ILEA declined by 14% sequentially, with the remainder of the sales contraction driven by normalization of wholesaler inventory levels. In contrast, ILEA-HD, the high-dose formulation, posted a 54% year-over-year sales increase but was essentially flat quarter-over-quarter, as demand growth was offset by inventory drawdown.

Diversification outside ophthalmology was a clear strength. Dupixent, Regeneron’s lead immunology asset, grew 20% globally and 19% in the U.S., maintaining leadership across multiple indications and launching into new markets such as chronic spontaneous urticaria and COPD. Libtio, an oncology therapy, grew 21% in the U.S., gaining share in lung and skin cancer indications. International sales and collaboration revenue, especially from Sanofi, contributed meaningfully, with Regeneron’s share of Sanofi collaboration profits up 27% year-over-year. Free cash flow was strong at $816 million, and the company maintained a net cash position after significant capital return through buybacks and dividends.

• Retinal Downturn: ILEA’s U.S. sales contraction was primarily due to patient affordability challenges and a shift to repackaged Avastin.
• Immunology and Oncology Growth: Dupixent and Libtio continued to gain share, supported by new indications and strong payer coverage.
• Operational Leverage: Collaboration revenue and disciplined SG&A spend helped offset margin pressure from inventory write-offs and product mix shifts.

The quarter highlighted Regeneron’s ability to drive growth outside its legacy retinal business, but also underscored its vulnerability to shifts in reimbursement and competitive intensity in the U.S. ophthalmology market.

Executive Commentary

Strategic Positioning

1. Retinal Franchise Faces Structural Headwinds

The rapid shift of patient volume from ILEA to lower-cost Avastin highlights a structural vulnerability in Regeneron’s U.S. retinal business. The funding gap at charitable copay assistance foundations exposed reliance on external support for patient access, especially among Medicare patients who lack supplemental coverage. Regeneron’s response—considering a matching program to stimulate broader philanthropic support—signals a search for more sustainable solutions, but near-term sales recovery remains uncertain. Management acknowledged persistent competitive pressure and a need for category-wide industry participation to restore funding stability.

2. Immunology Portfolio Anchors Growth and Pipeline Optionality

Dupixent’s continued expansion into new indications and geographies is central to Regeneron’s growth narrative. With approvals now spanning seven type II allergic diseases and blockbuster status in four, Dupixent is positioned as the standard of care in atopic dermatitis, asthma, and now chronic spontaneous urticaria. The COPD launch is outperforming previous indications, and upcoming regulatory milestones in bullous pemphigoid and other diseases offer further optionality. Payer coverage remains robust, and direct-to-consumer campaigns are being deployed to accelerate patient and physician awareness.

3. Oncology and Hematology Pipeline Advances

Libtio and late-stage hematology assets are building momentum as Regeneron targets best-in-class positioning in several cancer settings. Libtio’s share gains in lung and skin cancer, along with upcoming readouts and regulatory submissions for bispecific antibodies (limboseltamab, odrinexamab), support a multi-pronged oncology strategy. Combination regimens and differentiated safety profiles are key competitive levers, with pivotal data in melanoma and other solid tumors expected later this year.

4. R&D and Manufacturing Investment as Competitive Moat

Regeneron is deploying over $7 billion in U.S. manufacturing and R&D infrastructure to support its pipeline and scale future launches. Recent agreements with Fujifilm and ongoing facility expansions in New York reinforce its commitment to domestic capabilities, a strategic hedge against regulatory, tariff, and supply chain risks. This investment also supports the company’s ambition to remain a leading innovator in genetic medicines, obesity, and rare diseases.

5. Regulatory Scrutiny and Execution Risk

Multiple complete response letters (CRLs) and device-related regulatory delays expose execution risk and increased FDA scrutiny, particularly for third-party suppliers. Management attributed recent setbacks to heightened post-COVID regulatory standards and industry-wide contract manufacturing issues, but acknowledged the need for improved performance and transparency. The timeline for resolution of the ILEA-HD pre-filled syringe CRL remains uncertain, though management expects a relatively expeditious process.

Key Considerations

This quarter’s results underscore a shifting risk-reward calculus for Regeneron investors, as the company pivots from legacy ophthalmology dependence to a more diversified growth platform anchored by immunology and oncology.

Key Considerations:

• Patient Access Disruption: The anti-VEGF market’s sensitivity to copay assistance highlights the importance of sustainable patient support mechanisms for high-cost therapies.
• Pipeline Execution: Multiple late-stage readouts and regulatory decisions in 2025 will shape medium-term growth, especially in immunology and oncology.
• Capital Allocation Discipline: Aggressive share repurchases and dividend initiation reflect confidence in long-term cash generation, but also raise the bar for pipeline execution.
• Manufacturing and Regulatory Complexity: Third-party supplier issues and evolving FDA standards heighten operational risk, especially for device-based products.
• Tariff and Policy Uncertainty: Ongoing monitoring of U.S. pharmaceutical tariffs and political shifts may impact cost structure and access, though management sees limited near-term impact.

Risks

Regeneron faces material risks from reimbursement volatility, regulatory delays, and increased competitive intensity, particularly in its U.S. retinal franchise. The company’s exposure to patient assistance funding gaps and reliance on third-party suppliers for device components create operational unpredictability. Further, upcoming regulatory decisions and data readouts represent binary risk events that could impact near- and medium-term growth trajectories.

Forward Outlook

For Q2 2025, Regeneron expects:

• Continued pressure on ILEA U.S. sales due to copay funding uncertainty and competitive dynamics.
• Ongoing momentum in Dupixent and Libtio, with further growth from new indications and launches.

For full-year 2025, management updated guidance:

• Gross margin range lowered to 86-87% due to higher inventory write-offs.

Management emphasized the timing of regulatory resolutions and the ramp of new product launches as key variables for the remainder of the year.

• Multiple pivotal data readouts and regulatory milestones expected in immunology, oncology, and rare diseases.
• Potential for acceleration in ILEA-HD adoption if label expansions and device approvals are secured.

Takeaways

Regeneron’s Q1 revealed both the vulnerability of its legacy retinal business to external funding shocks and the resilience of its diversified growth engines.

• Retinal Franchise Under Pressure: The anti-VEGF market’s contraction and patient funding challenges are driving volume loss to lower-cost competitors, with no quick fix in sight.
• Immunology and Oncology Leadership: Dupixent and Libtio’s performance validates Regeneron’s pipeline-driven pivot, with new indications and global launches sustaining growth.
• Regulatory and Market Uncertainty: Investors should closely monitor regulatory timelines, funding environment developments, and execution on late-stage pipeline milestones for signs of inflection or further disruption.

Conclusion

Regeneron’s Q1 2025 results mark a decisive shift in its business mix, as legacy ophthalmology faces structural headwinds while immunology and oncology assets drive growth. The company’s ability to navigate regulatory, reimbursement, and operational complexity will be critical for sustaining long-term value creation.

Industry Read-Through

Regeneron’s experience this quarter offers a cautionary signal for the broader biopharma sector on the fragility of patient access models in the U.S. Medicare market. The rapid share shift in the anti-VEGF segment underscores the risk of over-reliance on charitable copay programs and the need for diversified payer strategies. Regulatory scrutiny of device components and third-party manufacturing is intensifying post-COVID, raising the bar for operational excellence across the industry. Companies with broad pipelines and robust capital allocation programs are better positioned to weather these shocks, but execution risk remains elevated for those with concentrated product exposure or complex supply chains.

REGN Healthcare Biotechnology Immunology Ophthalmology Oncology Pipeline Reimbursement